Valens GroWorks Corp (CSE:VGW,OTC:VGWCF) has released an in-depth article on the chemistry of the cannabis plant and its compounds and highlighted the need for extraction. According to Valens, extraction is necessary to purify and concentrate select compounds from the cannabis plant. When done correctly, extraction can provide pure and isolated compounds free of impurities that can negatively affect a user’s experience.

There are multiple extraction methods. Most methods utilize temperature, pressure, solvents and time to access the cannabinoids, flavonoids and terpenes present in cannabis. Regardless of the extraction method, extraction results in a more concentrated product, which can be dangerous if the plant contains toxins or heavy metals before being processed.


As one of the largest third-party cannabis extraction companies in Canada, Valens tests, analyzes and produces cannabis extracts for medical and recreational cannabis distributors. The company offers large capacity, in-house quality testing and various extraction services to other licensed producers such as Canopy Growth (TSX:WEED), Harvest One (TSXV:HVT) and Tilray (NASDAQ:TLRY), among others. Valens is currently able to process 240,000 kilograms of cannabis and meticulously tests its products for purity and safety throughout the process.

Overall, Valens believes that the future of the cannabis industry is moving towards extraction due to its versatility. Cannabis extracts can be packaged into oil capsules, vape cartridges and edibles, among other products. By offering several different extraction methods, Valens can ethically and sustainably produce various products for its clients with a wide array of cannabinoid and terpene profiles.

“The future of cannabis in Canada is coming and we are going to be at the forefront,”  said Valens CEO Tyler Robson.

To view the full article, click here.

Click here to connect with Valens GroWorks Corp (CSE:VGW,OTC:VGWCF)  for an Investor Presentation. 

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less